After an FDA endorsement Tuesday, CSL Behring and uniQure's hemophilia B gene therapy Hemgenix debuts not only as the first gene therapy approved for the rare disorder, but as the new most expensive drug in the world. The drug will sport an eye-popping price tag of $3.5 million per dose.
